CAJ | 학술논문

目的：探讨全脑放射治疗后服用厄洛替尼引起的头部皮肤放射治疗回忆反应。方法：对右肺腺癌(T3N2M1)骨转移患者行全脑放疗，DT：40 Gy，20次，4周。放疗结束后即开始服用厄洛替尼150 mg/d。结果：服用厄洛替尼第21 d，开始出现头部皮疹、毛囊炎及局部感染，并逐渐加重，按RTOG急性反应标准评为3级；皮肤严重反应界线与全脑放疗范围一致。停用厄洛替尼，对症处理5d后明显好转，考虑为厄洛替尼引起的放射治疗回忆反应。结论：放射治疗后服用厄洛替尼有可能引起回忆反应，程度严重时需减量或停药，并积极对症治疗。
목적：탐토전뇌방사치료후복용액락체니인기적두부피부방사치료회억반응。방법：대우폐선암(T3N2M1)골전이환자행전뇌방료，DT：40 Gy，20차，4주。방료결속후즉개시복용액락체니150 mg/d。결과：복용액락체니제21 d，개시출현두부피진、모낭염급국부감염，병축점가중，안RTOG급성반응표준평위3급；피부엄중반응계선여전뇌방료범위일치。정용액락체니，대증처리5d후명현호전，고필위액락체니인기적방사치료회억반응。결론：방사치료후복용액락체니유가능인기회억반응，정도엄중시수감량혹정약，병적겁대증치료。
Objective: Radiation recall dermatitis (RRD) occurs in a previously irradiated field and is triggered by certain cytotoxic drugs or target drugs. A case of RRD caused by treatment with erlotinib 21 days after whole brain radiation therapy (WBRT) is reported. PATIENT AND Methods: A 56-year-old female patient with boon metastase of non-small cell lung cancer (T3N2M1) was found brain metases in MRI without symptom 3 months after diagnosis. She was treated with WBRT (Dt40Gy/20f/4weeks) and erlotinib (150mg/day) thereafter. Results:The patient developed rash, folliculitis and localized infection in her head skin 21 days after the first dose of erlotinib (grade 3 Radiation Therapy Oncology Group scoring criteria). The severity lesions were localized to head skin which limited in scope of WBRT. Erlotinib was stop and treatment to lesions was applied. The diagnosis of RDD induced by erlotinib was made. Conclusion:The use of Erlotinib after RT may trigger RRD. We advise clinicians to be cautious of RRD after erlotinib treatment. The drug should be unused and the treatment to severity lesions should be applied.